1

13TH EUROPEAN ISSX MEETING

University of Strathclyde | Glasgow, Scotland

June 22-25, 2015

2

CO-CHAIRS:

Roland Wolf University of Dundee, Dundee, Scotland

Ann DalyNewcastle University, Newcastle upon Tyne, England

Dear colleagues and friends,

On behalf of the International Society for the Study of Xenobiotics (ISSX), you are warmly invited to join us at the 13th European ISSX Meeting which convenes June 22 - 25, 2015 at the University of Strathclyde’s Technology and Innovation Centre in Glasgow, Scotland.

The Meeting Organising Committee has carefully designed the programme to address key research topics including: PBPK Modelling, Stem Cell Technology Developments and their Application to Drug Metabolism and Drug Safety, the Role of Drug Transporters, Epigenomics in Drug Metabolism and Disease, Mass Spectrometry of Small Molecules, and much more. The meeting additionally will feature a wide range of contemporary research topics in the form of poster presentations as well as industry-sponsored educational sessions each morning prior to the general meeting. Complementing the meeting, top suppliers to the scientific community will present their products and services during the meeting exhibition.

The Meeting Organising Committee is particularly keen to encourage new investigators to use this meeting as a platform

to communicate their own research and to further their career progression. New investigators will meet leading researchers while learning, networking, and socialising with other delegates in a friendly yet stimulating environment. Discounted registration fees are available for ISSX members as well as pre- and postdoctoral students. Please visit the meeting web site at www.issx.org/Glasgow for information.

Attendees of the 13th European ISSX Meeting can experience first-hand the charming and vibrant city of Glasgow. There is a diverse array of cultural and entertainment options available along with an excellent dining scene. Supported by a great transportation network, meeting attendees and accompanying guests can take in all that this unique and beautiful city has to offer.

We are looking forward to welcoming you in Glasgow for an exciting and educational meeting!

Sincerely, C.R. Wolf, Ph.D., OBE Ann Daly, Ph.D. University of Newcastle Dundee University

Meeting Co-Chairs

MEETING ORGANISING COMMITTEE:

John HayesUniversity of Dundee, Dundee, Scotland

Brian HoustonUniversity of Manchester, Manchester, England

Neil KitteringhamUniversity of Liverpool, Liverpool, England

Michael McMahonUniversity of Dundee, Dundee, Scotland

Richard MeehanUniversity of Edinburgh, Edinburgh, Scotland

Munir PirmohamedUniversity of Liverpool, Liverpool, England

Colin SucklingUniversity of Strathclyde, Glasgow, Scotland

Geoff TuckerUniversity of Sheffield, Sheffield, England

Michael VoiceCypex, Ltd., Dundee, Scotland

Heather WallaceUniversity of Aberdeen, Aberdeen, Scotland

Matt WrightNewcastle University, Newcastle upon Tyne, England

JOIN US AT THE 13TH EUROPEAN ISSX MEETING

MEETING ORGANISING COMMITTEE

3

SHORT COURSE DESCRIPTIONSSHORT COURSE 1: MASS SPECTROMETRY IN DRUG METABOLISM STUDIES Chairs: Neil Kitteringham, University of Liverpool, Liverpool, UK and Ian Wilson, Imperial College, London, UK Early determination of metabolic stability and metabolic fate of compounds in drug discov-ery is seen as a key part of ensuring that compounds are only selected for further studies if they have properties that make them suitable for future development. The use of LC-MS is now ubiquitous by discovery teams to determine the pharmackokinetics, metabolic stability and the metabolic fate of drug candidates. This short course will illustrate how LC-MS is used to detect and identify metabolites, highlight metabolic “hot spots,” identify com-pounds with reactive metabolite liabilities, and enable structure optimization.

Short Course 2: Stem Cell Derived Tissues in Toxicology Chairs: Chris Goldring, University of Liverpool, Liverpool, UK and Matt Wright, Newcastle University, Newcastle upon Tyne, UKCurrent preclinical drug testing does not predict some forms of adverse drug reactions in humans. Adhering to the principles of the 3Rs, efforts at improving predictability of drug-in-duced tissue injury in man have included using stem cell technology to generate human cells for screening for adverse effects of drugs in man. This short course will explain the background to this area, why stem cells may be useful tools in the assessment tool-box to predict basic cellular perturbation, what we need from the cells, how to compare them with their terminally-differentiated human counterparts and what techniques are used to carry out this phenotyping. Real-world examples of how cells differentiated from stem cells are being deployed to investigate drug/chemical toxicity will be described. Four senior researchers in this field will present a background, and the following organ systems will be discussed in detail: liver, heart, and kidney.

Short Course 3: Physiologically Based Pharmacokinetic ModellingChairs: Geoff Tucker, Simcyp Limited, Sheffield, UK and Brian Houston, University of Manchester, Manchester, UKThe application of physiologically based pharmacokinetic (PBPK) modelling has come of age in drug development and regulation, reflecting significant advances over the past 20 years in the predictability of key pharmacokinetic parameters from human in vitro data, especially with respect to drug-drug interactions, and the availability of dedicated software platforms and associated data bases. This course will provide an understanding of the basic principles of in vitro – in vivo extrapolation; key issues will be illustrated with specific case studies, and the special considerations necessary to extend PBPK modelling to pre-dict paediatric drug doses will be explained. The current status of regulatory acceptance of simulations based on PBPK modelling will be discussed.

Short Course 4: New Horizons in Mass Spectrometry Chairs: Andy Pitt, Aston University, Birmingham, UK and Neil Kitteringham, University of Liverpool, Liverpool, UKThis short course aims to provide an overview of the exciting, new, and innovative applica-tions for mass spectrometry in the study of xenobiotics and their interactions with proteins. The interface between small molecules and biological macromolecules is at the heart of both drug efficacy and xenobiotic toxicity—mass spectrometry offers the perfect platform to explore this interface. The first three talks explore different approaches to deploy mass spectrometry within this context, whilst the final talk addresses the thorny issue of dealing with large data sets from both metabolomics and proteomic studies.

4

SCIENTIFIC PROGRAM AS OF JANUARY 2, 2015

SHORT COURSES

SHORT COURSE 1: Mass Spectrometry in Drug Metabolism StudiesChairs: Ian Wilson, Imperial College, London, United Kingdom and Neil Kitteringham, University of Liverpool, Liverpool, United Kingdom

LC-MS in Metabolite Identification in High Throughput Drug DiscoveryAnthony Dickie, Evotec (UK) Ltd., Abingdon, United Kingdom

Detecting and Identifying Reactive MetabolitesSara Amberntsson, AstraZeneca, Molndal, Sweden

The Use of LC-MS for Comprehensive Metabolite Characterisation and IdentificationRussell Mortishire-Smith Waters, Wilmslow, United Kingdom

Tips, Tricks and LC-ICPMS for Metabolite Detection and IdentificationIan Wilson, Imperial College, London, United Kingdom

SHORT COURSE 2: Stem Cell Derived Tissues in ToxicologyChairs: Chris Goldring, University of Liverpool, Liverpool, United Kingdom and Matt Wright, Newcastle University, Newcastle upon Tyne, United Kingdom

The Application of Stem Cells in Toxicology: What do We Need and Why do We Need Them?Chris Goldring, University of Liverpool, Liverpool, United Kingdom

Derivation of Cardiomycytes, Stem Cells, and Toxicity TestingChris Denning, University of Nottingham, Nottingham, United Kingdom

Stem Cell-Derived Renal CellsDaniele Zink, Institute of Bioengineering and Nanotechnology, Singapore

Hepatocyte Stem Cells in Toxicity TestingMatt Wright, Newcastle University, Newcastle upon Tyne, United Kingdom

SHORT COURSE 3: Physiologically Based Pharmacokinetic ModellingChairs: Geoff Tucker, Simcyp Limited, Sheffield, United Kingdom and Brian Houston, University of Manchester, Manchester, United Kingdom

Principles of IVIVEMichael Gertz, Roche, Basel, Switzerland

PBPK Case StudiesKaren Rowland-Yeo, Simcyp Limited, Sheffield, United Kingdom

Paediatric PBPK ModellingKay Ogunbero, University of Manchester, Manchester, United Kingdom

A European Regulatory Perspective on PBPK ModellingTerry Shepard, Medicines and Healthcare Products Regulatory Agency (MHRA), Slough, United Kingdom

SHORT COURSE 4: New Horizons in Mass SpectrometryChairs: Andy Pitt, Aston University, Birmingham, United Kingdom and Neil Kitteringham, University of Liverpool, Liverpool, United Kingdom

New Applications of Proteomics in Biomedical ResearchAndy Pitt, Aston University, Birmingham, United Kingdom

Imaging for Xenobiotics and MetabolitesMalcolm Clench, Sheffield Hallam Uniersity, Sheffield, United Kingdom

5

Data Independent Acquisition: A New Era for Quantitative Proteomics?Roz Jenkins, University of Liverpool, Liverpool, United Kingdom

Making Sense of the Data: How to Handle Large Proteomic and Metabolomics DatasetsKarl Burgess, University of Glasgow, Glasgow, United Kingdom

SYMPOSIA

KEYNOTE ADDRESS: Protein Kinases as Drug TargetsChair: Roland Wolf, University of Dundee, Dundee, United KingdomSpeaker: Professor Sir Philip Cohen, University of Dundee, Dundee, United Kingdom

SYMPOSIUM 1: Recent Developments in Stem Cell Technology and its Application to Drug Metabolism and Drug Safety TestingChairs: David Hay, University of Edinburgh, Edinburgh, United Kingdom and Ludovic Vallier, University of Cambridge, Cambridge, United Kingdom

Pluripotent Stem Cell Hepatocytes and Tissue EngineeringDavid Hay, University of Edinburgh, Edinburgh, United Kingdom

Pluripotent Stem Cell Hepatocytes and Cholangiocyte ModelsLudovic Vallier, University of Cambridge, Cambridge, United Kingdom

Animal ModelsStephen Strom, Karolinska Institute, Stockholm, Sweden

SYMPOSIUM 2: Expanding the Boundaries of PKPD ModellingChairs: Geoff Tucker, Simcyp Limited, Sheffield, United Kingdom and Brian Houston, University of Manchester, Manchester, United Kingdom

Systems PharmacologyMeindert Danhof, Leiden University, Leiden, Netherlands

Modelling in ToxicityTarjinder Sahota, GlaxoSmithKline, Uxbridge, United Kingdom

Incorporating Transporter Kinetics into PBPK ModelsAlexandra Galetin, University of Manchester, Manchester, United Kingdom

PBPK Modelling of mABsLinzhong Li, Simcyp Limited, Sheffield, United Kingdom

SYMPOSIUM 3: Systems ToxicologyChairs: Paul Watkins, The Hamner Institues for Health Sciences, Research Triangle Park, NC, United States and Bob van de Water, Leiden University, Leiden, Netherlands

Systems Microscopy to Unravel the Wiring of Toxicity Pathways in Drug-induced Liver InjuryBob van de Water, Leiden University, Leiden, Netherlands

A Quantitative Systems Biology Analysis of Signal Transduction Networks Underlying DILIUrsula Klingmüller, DKFZ, Heidelberg, Germany

Systems Modelling Approaches to Predict Idiosyncratic DILIPaul Watkins, The Hamner Institues for Health Sciences, Research Triangle Park, NC, United States

Integration of QSAR and PK-PD Modelling in Cardiac Drug Safety AssessmentSebastian Polak, Simcyp Limited, Sheffield, United Kingdom

6

SYMPOSIUM 4: Clinical Implementation of PharmacogenomicsChairs: Ann Daly, Newcastle University, Newcastle upon Tyne, United Kingdom and Matthias Schwab, Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany

Implementation of Pharmacogenomics in Clinical Practice-focus on Evidence-based Medicine and Cost-effectivenessMunir Pirmohamed, University of Liverpool, Liverpool, United Kingdom

Importance of Drug Transporter Polymorphisms and Scope for Clinical ImplementationMatthias Schwab, Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany

Pharmacogenomic Approaches to Treatment of Cystic FibrosisMargareta Amaral, University of Lisboa, Lisbon, Portugal

HLA Genotype and Risk of Adverse Drug Reaction: Prospects for Clinical ImplementationDuncan McHale, UCB Pharma, Stockport, United Kingdom

SYMPOSIUM 5: Role of Drug Transporters: Current and Future Perspectives (an ITC Sponsored Symposium)Chairs: Donald Tweedie, Boehringer Ingelheim, Ridgefield, CT, United States and Brian Houston, University of Manchester, Manchester, United Kingdom

Regulatory ViewEva Gil Berglund, Medical Products Agency, Uppsala, Sweden

N1-methylnicotinamide: An Endogenous Probe for Drug Interactions by Renal Cation Transporters?Martin Fromm, University of Erlangen-Nuremberg, Erlangen, Germany

Predictions of Cellular Drug Binding and Implications for Intracellular Drug Concentrations and EffectsPar Matsson, Uppsala University, Uppsala, Sweden

Substrate/Inhibition Assays and Prediction of DDIsChristoph Funk, F. Hoffmann-La Roche Ltd., Basel, Switzerland

SYMPOSIUM 6: Advances in Pathways of Chemically-induced Oxidative Stress and DNA DamageChairs: John Hayes and Ken Tew

Control of Redox Homeostasis by the Nrf2 Regulatory NetworkJohn Hayes, University of Dundee, Dundee, United Kingdom

Regulation of Protein Function by Glutathionylation During Oxidative StressKenneth Tew, Medical University of South Carolina, Charleston, SC, United States

The Redox Chemistry of AntioxidantsClaus Jacob, Saarland University, Saarland, Germany

Control of H2O2 Transport in and Between CellsRoberto Sitia, San Raffaele Scientific Institute, Milan, Italy

SYMPOSIUM 7: Humanised Animal Models in Drug DevelopmentChairs: Colin Henderson, University of Dundee, Dundee, United Kingdom and Frank Gonzalez, National Cancer Institute, Bethesda, MD, United States

Humanised Mouse Models of Drug MetabolismColin Henderson, University of Dundee, Dundee, United Kingdom

Mouse Models for Elucidation of CYP2D6 and CYP2C19 Function in the Developing and Adult BrainMagnus Ingelman-Sundberg, Karolinska Institute, Stockholm, Sweden

Knockout and Humanised Mouse Models for Detoxifying ProteinsAlfred Schinkel, The Netherlands Cancer Institute, Amsterdam, Netherlands

Lipoprotein and Bile Acid Profiles in FRG Mice with Humanised LiversEwa Elis, Karolinska Institute, Stockholm, Sweden

SYMPOSIUM 8: The Contribution of the Gut Microbiome to Drug Metabolism, Drug Interactions and Drug ToxicityChairs: Heather Wallace, University of Aberdeen, Aberdeen, United Kingdom and Elaine Holmes, Imperial College London, London, United Kingdom

Microbiome MetabolomicsElaine Holmes, Imperial College London, London, United Kingdom Impact of Host-microbial Interactions on Toxicokinetics of TacrineEric Chan, National University of Singapore, Singapore

Lecture Title PendingSven Pettersson, Karolinska Institute, Stockholm, Sweden

Diet-microbiome InteractionsBernard Corfe, University of Sheffield, Sheffield, United Kingdom

SYMPOSIUM 9: Epigenomics in Drug Metabolism and DiseaseChairs: Richard Meehan, Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom and Jonathan Moggs, Novartis, Basel, Switzerland

Epigenomics: Impact for Translational SciencesJonathan Moggs, Novartis, Basel, Switzerland

5hmC – Tissue Specificity and Modulation by XenobioticsJohn Thomson, Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom

Genetic-Epigenetic Interactions and Implications for Genome Stability/FunctionThomas Carell, Ludwig-Maximilians University, Munich, Germany

Spatial Organisation of the Nucleus and Influence on Human DiseaseWendy Bickmore, Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom

SYMPOSIUM 10: Proteins as Targets for Covalent Modification by Xenobiotics: Therapeutic Opportunities versus Toxicological RiskChairs: Thomas Baillie, University of Washington, Seattle, WA, United States and Kevin Park, University of Liverpool, Liverpool, United Kingdom

Pharmacological, Physiological, and Pathological Consequences of Drug Bioactivation and Covalent BindingKevin Park, University of Liverpool, Liverpool, United Kingdom

Reactive Drug Metabolites and Targeted Covalent Inhibitors: A Risk-Benefit PerspectiveThomas Baillie, University of Washington, Seattle, WA, United States

Challenges in Developing AZD9291 – An Irreversible Inhibitor of EGFR-TKI Sensitising and Resistant Mutations in Non-small Cell Lung CancerPeter Ballard, AstraZeneca, Cheshire, United Kingdom

Inhibitors of Cathepsin C: Not Your Typical Oral Small MoleculesMichael Palovich, GlaxoSmithKline, Uxbridge, United Kingdom

7

8

SYMPOSIUM 11: Predicting Human Responses During Drug Discovery and DevelopmentChairs: Roland Wolf, University of Dundee, Dundee, United Kingdom and Peter Moldeus, Karolinska Institute, Stockholm, Sweden

Application of in vivo Reporters for Stress Responses in Drug DevelopmentRoland Wolf, University of Dundee, Dundee, United Kingdom

In vitro Approaches to Toxicity TestingRuth Roberts, AstraZeneca, Stockport, United Kingdom

Establishing Potential Safety Liabilities in Early Drug DevelopmentBill Pennie, Takeda, Norwich, CT, United States

The Application of Epigenome and Kinome-based Bioassays for Risk AssessmentIvonne Rietjens, Wageningen University, Wageningen, Netherlands

SYMPOSIUM 12: Conjugating Enzymes and Hydrolases in Endogenous and Foreign Compound MetabolismChairs: Michael Arand, University of Zurich, Zurich, Switzerland and John Miners, Flinders University, Adelaide, Australia

Microsomal (and Soluable) Epoxide Hydrolase in Eicosanoid Metabolism and its Physiological ConsequencesAnne Marowsky, University of Zurich, Zurich, Switzerland

DDIs Involving Glucuronidated DrugsJohn Miners, Flinders University, Adelaide, Australia

Role of SULTs in Metabolic ActivationHansruedi Glatt, German Institute of Human Nutrition, Potsdam, Germany

Carboxylesterase 1 – Substrates, Regulation of Enzyme Activity and PharmacogeneticsHenrik Rasmussen, Region Hovedstadens Psykiatri, Copenhagen, Denmark

PLENARY SESSION: Inflammation: Effects on Drug Metabolism and Disease AetiologyChairs: Kathie Knights, Flinders University, Adelaide, Australia and Eddie Morgan, Emory University, Atlanta, GA, United States

Regulation of Drug Transporters in Inflammation: Impact on Drug DispositionMicheline Piquette-Miller, University of Toronto, Toronto, Canada

Inflammatory Regulation of Human Drug Metabolising EnzymesUlrich Zanger, Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany

Role of NO in Inflammatory Regulation of Drug Metabolising EnzymesEdward T. Morgan, Emory University, Atlanta, GA United States

Inflammation and Liver DiseasePercy Knolle, Technische Universität München, Munich, Germany

SPECIAL KEYNOTE CLOSING LECTUREChairs: Roland Wolf, University of Dundee, Dundee, United Kingdom and Ann Daly, Newcastle University, Newcastle upon Tyne, United KingdomSpeaker: Frank Gonzalez, National Cancer Institute, Bethesda, MD, United States

9

REGISTRATION INFORMATIONThe meeting registration fee includes admittance to:• Scientific Symposia and Special Lectures• Awards Presentation and Lectures• Poster Presentations• Poster Awards Competition Review and Awards Session• Exhibition• Civic Reception• Opening Welcome Reception

The short courses are separately ticketed offerings and may be added to a registration at an additional fee.

REGISTRATION FEES All Prices in US Dollars

PLEASE NOTE: The meeting registration fee does not include access to the short courses nor the ISSX social event at the Old Fruit Market. Guest registration includes a meeting tote bag and admission to the opening welcome reception, Civic Reception, and all refreshment breaks. Guest registration does not include admittance to the scientific sessions or the ISSX social event at the Old Fruit Market. Tickets to the social event may be purchased for guests in advance.

MEETING CANCELLATION POLICYRegistration fees for the meeting and for short courses, less an administrative processing fee of $100 USD, will be refunded if a written/emailed request is received on or before Monday, June 1, 2015. No refunds can be issued past this date as ISSX is required to provide guarantees and pay deposits for various meeting services based on anticipated attendance. Thank you for your understanding.

Early Regular On-Site January 1—March 20 March 21—June 21 June 22—25

ISSX Member $175 $225 $250

Nonmember $225 $275 $325

Student Member $100 $125 $150

Student Non-Member $125 $150 $175

SHORT COURSES

Early Regular On-Site January 1—March 20 March 21—June 21 June 22—25

ISSX Member $615 $715 $795

Nonmember $775 $845 $955

Student Member $250 $275 $300

Student Non-Member $275 $300 $325

Guest $50 $50 $50

MEETING REGISTRATION

SOCIAL PROGRAMOpening Welcome Reception

Start the meeting at the Opening Welcome Reception in the exhibition and poster area of the Technology and Innovation Centre on Monday, June 22. Enjoy hors d’oeuvres and drinks while you meet with our meeting exhibitors and fellow attendees. Included with full meeting registration and guest ticket purchase.

Civic Reception

The Glasgow City Council would like to welcome ISSX to Glasgow with a Civic Reception on Tuesday, June 23 at 18:30. This unique event will be held in the prestigious surroundings of the City Chambers in the Picture Gallery. The Lord Provosts of the City will be in attendance to greet delegates and welcome you to Glasgow. The City Chambers is in the very heart of Glasgow and is one of the city’s most important and prestigious buildings. A grand and imposing edifice overlooking George Square, the City Chambers is an impressive symbol of Glasgow’s political strength and historical wealth. Completed in 1888, the City Chambers has for over 100 years been the headquarters of successive councils serving the City of Glasgow.

Complimentary - Advanced registration required.

Meeting Dinner and Ceilidh

Join us at the premier social event of the meeting at the Old Fruit Market of Glasgow which has kept all of its period charm, including its lofty vaulted roof, cast iron columns, balcony, and slender Victorian architecture. Attendees will enjoy a delicious buffet dinner, drinks, and a ceilidh. The word ceilidh (kay-lee) descended from the Gaelic word for “gathering” or “party”… However, these days when people think of a ceilidh, they think of a fun filled night of dancing, good music, and great company! The beauty of a ceilidh is that everyone can take part. You will be walked through the steps under the watchful eye of the professional caller who will be with you every step of the way – walking you through the moves before each dance and continuing to call out helpful hints throughout the rest of the dances. It is sure to be a wonderful time.

Make plans to join us at the Old Fruit Market on Wednesday, June 24.

Separate registration fee applies.

10

GENERAL INFORMATIONMeeting Location

University of StrathclydeTechnology and Innovation Centre121 George StreetGlasgow, Scotland G1 1RD

Accommodations

ISSX has arranged for special rates at several hotels in different price categories in the area near the Technology and Innovation Centre in Glasgow. The hotels are within walking distance to the meeting facility. Attendees are welcome to secure lodging at alternative venues.

Reservations for hotels in our housing block will be accepted on a first-come, first-served basis. A limited number of hotel rooms are available at each property. Reservations will be accepted based upon availability up to two weeks before our meeting convenes. It is to the attendee’s advantage to reserve their hotel accommodations as soon as possible.

Reserve lodging via this web site: www.issx.org/13euro/hotel

Awards Program

Nominations are currently being accepted for the scientific achievement awards for established and new investigators to be presented at the 13th European ISSX Meeting in June 2015 in Glasgow. Visit www.issx.org/nominations for details and to submit a nomination.

Climate/Time Zone

The month of June is characterized by gradually rising daily high temperatures, with daily highs around 17° C (63°F) throughout the month, sometimes exceeding 23° C (73°F). The daily low temperature ranges from 8° C (47°F) to 11° C (51°F).

Glasgow is located in the Greenwich Mean Time zone and Daylight Savings Time will be observed at the time of the meeting.

Exhibit Hall

Top suppliers will be on hand to share the latest products and services to help you advance your research. Bring plenty of business cards.

Language

The official language of the 13th European Meeting is English. All abstracts and presentations will be in English. No simultaneous translation will be available.

11

All images © Glasgow Chamber of Commerce

For complete information about travel to Glasgow, dining, culture,

sightseeing, and more, visit

www.peoplemakeglasgow.com

Vis

it w

ww

.issx

.org

fo

r th

e la

test

info

rmat

ion

ab

out

up

com

ing

ISS

X m

eeti

ngs:

20th

Nor

th A

mer

ican

ISS

X M

eetin

gO

rland

o, F

lorid

a, U

SA

| O

ctob

er 1

8 -

22, 2

015

11th

Inte

rnat

iona

l IS

SX

Mee

ting

Bus

an, K

orea

| J

une

12 -

16,

201

6

21st

Nor

th A

mer

ican

ISS

X M

eetin

gP

rovi

den

ce, R

hod

e Is

land

| S

epte

mb

er 2

4 -

28, 2

017

2025

M S

tree

t N

W,

Sui

te 8

00W

ashi

ngto

n, D

C 2

0036

US

A

Firs

t C

lass

M

ailin

g In

dic

ia

Reg

iste

r to

day

for

the

13th

Eur

opea

n IS

SX

Mee

ting

June

22

– 25

, 201

5 |

Gla

sgow

, Sco

tland

The

Inte

rnat

iona

l So

ciet

y fo

r th

e S

tud

y o

f X

eno

bio

tics

(IS

SX

) is

the

pre

mie

r in

tern

atio

nal

scie

ntifi

c or

gani

zatio

n fo

r re

sear

cher

s in

tere

sted

in t

he m

etab

olis

m, d

isp

ositi

on, a

nd

tran

spor

t of

xen

obio

tics

and

in o

ther

rel

ated

dis

cip

lines

. Our

mis

sion

is t

o p

rom

ote

scie

ntifi

c d

evel

opm

ent

and

to

fost

er c

omm

unic

atio

n am

ong

rese

arch

ers

wor

ldw

ide.